MedTrace Logo

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

NCT06192888 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

Conditions

Interventions

DRUG

Glofitamab

IV Glofitamab

DRUG

Obinutuzumab

IV Obinutuzumab

DRUG

Lenalidomide

Oral Lenalidomide

Sponsors & Collaborators

Principal Investigators

  • Anita Kumar, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2028-01-08
Completion
2028-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06192888 on ClinicalTrials.gov